Astra falls 9% after Wainua misses primary endpoint in late-stage trial
AstraZeneca's stock fell ~9% after its Wainua (eplontersen) therapy missed the primary endpoint in a late-stage clinical trial. The trial failure removes a meaningful near-term revenue catalyst and raises questions about the breadth of AstraZeneca's cardiovascular/neurological pipeline.
File photo · AstraZeneca’s Discovery Centre, Cambridge · Nov 2021 · John Sutton · CC BY-SA 2.0 · Source & licenseThe story
AstraZeneca shares dropped roughly 9% after Wainua (eplontersen), its RNA-targeting therapy developed with Ionis Pharmaceuticals, failed to meet the primary endpoint in a late-stage clinical trial. A Phase 3 miss of this magnitude typically signals that regulatory approval in this indication is off the table without further study design changes or additional trials.
Wainua had represented a meaningful pipeline asset for AstraZeneca, particularly in the cardiometabolic and rare disease space. Ionis Pharmaceuticals, AstraZeneca's partner on eplontersen, is also directly affected, as the collaboration underpins a significant portion of Ionis's commercial-stage revenue outlook. A failed primary endpoint puts milestone payments and royalty streams tied to this program in jeopardy.
The 9% single-day drop in AstraZeneca is notable for a large-cap pharma name, suggesting the market had priced in meaningful probability of success for this indication. The bear case here is straightforward: the trial failure is a binary negative event, and near-term re-rating pressure is likely to persist as analysts revise revenue models to strip out this program.
The bull case rests on AstraZeneca's broad and diversified pipeline — the company has multiple late-stage assets across oncology, respiratory, and rare disease that are unaffected by this result. Whether the selloff represents an overreaction depends on how much of AZN's valuation was attributable to Wainua's upside.
Our read · Thu, Jul 9
AZN and IONS are under pressure after Wainua's Phase 3 miss — the question is whether the selloff is an overreaction given AZN's diversified pipeline or fair repricing of lost milestone and royalty potential.
Why. A primary endpoint miss in a late-stage trial is a binary negative catalyst with no near-term reversal mechanism — analysts must revise models to remove this program, and that process typically extends selling pressure for 1-2 weeks post-announcement. The 9% gap down suggests the market was pricing in meaningful probability of success.
Both cases
What could change this view: AZN's diversified pipeline and any positive read-across from other ongoing trials could stabilize or reverse the selloff quickly; short covering after the initial gap could squeeze near-term.
Who reported it · 1
Keep reading
More on AZN
Olema shares slide 15.1% after AstraZeneca SERENA-4 resultsAstraZeneca breast cancer drug fails late-stage trial goalAmgen and AstraZeneca report positive lung cancer trial resultsAstraZeneca discontinues lung cancer trial of volrustomigAstraZeneca's $400bn deal unravels after investor oppositionLatest on the Wire
AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →Latest on the Wire
Trump Media buys back $100 million of notes ahead of Nov. 30 cash demandTrump, Xi and Putin pledge more refined fuel after first trilateral summitSky reserve linked to $518 million in illicit activity, investigation findsBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%Continue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by Investing.com, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →